Figure 5.

In vivo effects of MS-27-275 against human tumor xenografts. (A) Antitumor efficacies against human tumor xenografts. The effects of MS-27-275 at doses of 12.3 (⋄), 24.5 (○) and 49 mg/kg (●), Compound 2 at 98 mg/kg (└), and 5-FU at 30 (▴) and 40 mg/kg (▾) were examined as described in Materials and Methods. □ represents the control group. Vertical bars indicate standard errors. ∗, P < 0.05; ∗∗, P < 0.01, respectively, by Dunnett’s test or Steel’s test. The discontinued line in the Calu-3 experiment was caused by death of mice in the test group. (B) Increase of histone acetylation in HT-29 tumor xenografts. MS-27-275 (49 mg/kg) and compound 2 (49 mg/kg) were administered orally to the nude mice with HT-29 tumors (tumor size average, 179 mm³). At the indicated period after the administration, tumor samples were removed, and histones were extracted and analyzed as described in Materials and Methods. A representative of three similar observations is shown.